Advanced search
Publication Cover
Expert Review of Clinical Pharmacology Volume 4, 2011 - Issue 5
Submit an article Journal homepage
176
Views
13
CrossRef citations to date
0
Altmetric
Key Paper Evaluation

Potential mechanisms of efficacy and adverse effects in the use of fingolimod (FTY720)

Daniel Ontaneda The Mellen Center for Multiple Sclerosis Treatment and Research, Neurological Institute, Cleveland Clinic, Cleveland, OH 44195, USA; The Mellen Center for Multiple Sclerosis Treatment and Research, Neurological Institute, Cleveland Clinic, Cleveland, OH 44195, USA
&
Jeffrey A Cohen The Mellen Center for Multiple Sclerosis Treatment and Research, Neurological Institute, Cleveland Clinic, Cleveland, OH 44195, USA;[email protected]
Pages 567-570 | Published online: 10 Jan 2014

Citations (13)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Fabiana Auricchio, Cristina Scavone, Daniela Cimmaruta, Gabriella Di Mauro, Annalisa Capuano, Liberata Sportiello & Concetta Rafaniello. (2017) Drugs approved for the treatment of multiple sclerosis: review of their safety profile. Expert Opinion on Drug Safety 16:12, pages 1359-1371.
Read now
Emmanuel E. Egom, Robert A. Rose, Ludwig Neyses, Handrean Soran, John G. F. Cleland & Mamas A. Mamas. (2013) Activation of sphingosine-1-phosphate signalling as a potential underlying mechanism of the pleiotropic effects of statin therapy. Critical Reviews in Clinical Laboratory Sciences 50:3, pages 79-89.
Read now

Articles from other publishers (11)

Maria Pino, Sara Paganini, Claire Deleage, Kartika Padhan, Justin L. Harper, Colin T. King, Luca Micci, Barbara Cervasi, Joseph C. Mudd, Kiran P. Gill, Sherrie M. Jean, Kirk Easley, Guido Silvestri, Jacob D. Estes, Constantinos Petrovas, Michael M. Lederman & Mirko Paiardini. (2019) Fingolimod retains cytolytic T cells and limits T follicular helper cell infection in lymphoid sites of SIV persistence. PLOS Pathogens 15:10, pages e1008081.
Crossref
Anwen Shao, Zhiyuan Zhu, Lingfei Li, Shizhong Zhang & Jianmin Zhang. (2019) Emerging therapeutic targets associated with the immune system in patients with intracerebral haemorrhage (ICH): From mechanisms to translation. EBioMedicine 45, pages 615-623.
Crossref
Daniel Müller, Benedikt Frank & Christoph Kleinschnitz. (2017) Welcher MS-Patient braucht was?. DNP - Der Neurologe & Psychiater 18:3, pages 25-35.
Crossref
Michelle J. Kim, M. Tariq Bhatti & Fiona Costello. (2016) Famous. Survey of Ophthalmology 61:4, pages 512-519.
Crossref
Wai Y. Sun, David P. Dimasi, Melissa R. Pitman, YiZhong Zhuang, Robert Heddle, Stuart M. Pitson, Michele A. Grimbaldeston & Claudine S. Bonder. (2016) Topical Application of Fingolimod Perturbs Cutaneous Inflammation. The Journal of Immunology 196:9, pages 3854-3864.
Crossref
T. John Martin & Natalie A. Sims. (2015) Calcitonin Physiology, Saved by a Lysophospholipid. Journal of Bone and Mineral Research 30:2, pages 212-215.
Crossref
A.M. James Shapiro & Camillo Ricordi. 2014. Textbook of Organ Transplantation. Textbook of Organ Transplantation 1314 1333 .
Wendy S Vargas & Jai S Perumal. (2013) Fingolimod and cardiac risk: latest findings and clinical implications. Therapeutic Advances in Drug Safety 4:3, pages 119-124.
Crossref
William B. Rolland, Tim Lekic, Paul R. Krafft, Yu Hasegawa, Orhan Altay, Richard Hartman, Robert Ostrowski, Anatol Manaenko, Jiping Tang & John H. Zhang. (2013) Fingolimod reduces cerebral lymphocyte infiltration in experimental models of rodent intracerebral hemorrhage. Experimental Neurology 241, pages 45-55.
Crossref
Daniel Ontaneda & Daniela Di Capua. (2012) Benefits versus risks of latest therapies in multiple sclerosis: a perspective review . Therapeutic Advances in Drug Safety 3:6, pages 291-303.
Crossref
G. Cocco. (2012) A Patient with Leiden V Mutation, Multiple Sclerosis, Psoriasis, and Sicca Syndrome: Could Celecoxib and Fingolimod Adversely Affect the Heart?. Cardiovascular Toxicology 12:3, pages 266-272.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.